Automated Implantation of Artificial Mitral Chords: Preliminary Results from the Feasibility Trial.
A novel chordal system enables automated implantation of artificial mitral chords to treat mitral regurgitation (MR). This paper summarizes the "first-in-man" initial clinical results. The CHAGALL trial is a single arm, multi-center, prospective study to test the feasibility of this system for mitral repair. The interim clinical and echocardiographic results of the first 5 patients with a 12 months follow-up are presented. Five patients (mean age 64 years) with severe MR received implantation of neochords with this device under cardiopulmonary bypass. Technical success was obtained in all patients. TEE showed either no or trace residual MR (<1+/4+) following repair. Survival at 30 days was 100% and no device-related complication occurred. Reduction of mitral regurgitation was sustained up to 12 months. This novel chordal system is promising because it greatly facilitates the deployment of neochords to repair the mitral valve. Results at 12 months are encouraging. The device is currently under development for transcatheter approach.